Anthropic Enters Drug Discovery Race With Claude Science
By Suad Seferi ·
SAN FRANCISCO — Anthropic is moving deeper into scientific research and drug discovery with the launch of Claude Science, a new AI workbench designed to help scientists analyze data, run computational workflows and explore biological research more efficiently. The company says Claude Science is now available in beta for paid Claude users. Unlike a new standalone model, the product is a research environment built around Claude, allowing scientists to work with code, datasets, scientific databases and visual artifacts such as protein structures, genome tracks and chemical structures. Anthropic says the tool can trace results back to the code that produced them and includes a reviewer agent to check citations and calculations. The launch marks Anthropic’s strongest move yet into the life sciences sector, where AI companies are increasingly competing to support pharmaceutical research, molecular design and biomedical analysis. The bigger signal, however, is not only the product launch. Anthropic is also planning its own preclinical drug-discovery programs, with an initial focus on neglected diseases, according to reports. That would move the company beyond providing AI tools for researchers and pharmaceutical companies, and closer to becoming a direct actor in drug development. Claude Science is designed to support areas such as genomics, proteomics, structural biology and cheminformatics. The product can connect to more than 60 scientific databases and domain-specific models, while running analysis through local or connected computing environments. Anthropic’s documentation says the app is available on macOS and Linux and keeps user files on the researcher’s computer while running code in a sandbox. The move comes as AI companies look for more specialized markets beyond general-purpose chatbots. Scientific research has become one of the most attractive areas because it combines large datasets, complex workflows and high commercial value. Drug discovery, in particular, is seen as a field where AI could help researchers identify targets, analyze molecules and reduce some of the early-stage work that traditionally takes years. But the road from AI-generated insight to approved medicine remains long. Experts have cautioned that AI can assist discovery, but it cannot replace laboratory validation, clinical trials or regulatory review. No AI-designed drug has yet received approval from the U.S. Food and Drug Administration, and successful drug development can still take more than a decade. For the wider AI industry, Anthropic’s move shows how frontier AI companies are shifting from general productivity tools toward sector-specific systems. Google DeepMind has already made major advances in protein structure prediction, while other companies are building AI tools for chemistry, biology and pharmaceutical research. For users in Europe and the Balkans, the development is also relevant beyond medicine. It shows where the next phase of AI competition is moving: from chatbots and coding assistants toward research infrastructure, regulated industries and high-stakes scientific work. That shift will raise new questions for governments, universities and healthcare systems. If AI tools become part of scientific and medical discovery, institutions will need stronger rules for validation, safety, data governance and accountability. Anthropic is presenting Claude Science as a way to make research workflows faster and more reproducible. Whether it can help produce real medical breakthroughs remains an open question. What is clear is that the AI race is no longer only about who builds the best chatbot. It is increasingly about who can turn AI into infrastructure for science.